NCT06553638View on ClinicalTrials.gov

Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloproliferative Neoplasia (PRODIGE)

Active, not recruitingOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Myeloproliferative Neoplasm

Trial Locations (1)

29609

Chu Brest, Brest

All Listed Sponsors

lead

University Hospital, Brest

OTHER